Home Cart Sign in  
Chemical Structure| 1693758-51-8 Chemical Structure| 1693758-51-8

Structure of Eganelisib
CAS No.: 1693758-51-8

Chemical Structure| 1693758-51-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

IPI-549 is a selective phosphoinositide-3-kinase (PI3K)-γ inhibitor with IC50 of 16 nM as an immuno-oncology clinical candidate.

Synonyms: IPI-549

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Eganelisib

CAS No. :1693758-51-8
Formula : C30H24N8O2
M.W : 528.56
SMILES Code : O=C(C1=C2N=CC=CN2N=C1N)N[C@H](C3=CC4=C(C(N3C5=CC=CC=C5)=O)C(C#CC6=CN(C)N=C6)=CC=C4)C
Synonyms :
IPI-549
MDL No. :MFCD30533720
InChI Key :XUMALORDVCFWKV-IBGZPJMESA-N
Pubchem ID :91933883

Safety of Eganelisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Eganelisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    PI3Kγ, IC50:16 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDSCs 2 µg/mL 12 hours To evaluate the inhibitory effect of LIC on MDSCs, results showed that LIC significantly reduced Arg-1 and ROS levels and promoted MDSCs apoptosis PMC8292876
M2 macrophages derived from RAW264.7 cells 5 μM 14 days The combination of IPI-549 and PTX completely inhibited 3D MTC growth, while the combination of IPI-549 with other chemotherapeutic agents (doxorubicin and gemcitabine) did not show improvement compared to single drug treatment. PMC9589917
DC2.4 cells 100 µL 3 hours To observe the uptake of PMA-NeoV by DCs PMC8883272
miPS-LLCcm 14.6 μM 48 hours Inhibited proliferation, self-renewal, migration, and invasion of miPS-LLCcm cells and induced apoptosis PMC8748513
miPS-PK8cm 18.1 μM 48 hours Inhibited proliferation, self-renewal, migration, and invasion of miPS-PK8cm cells and induced apoptosis PMC8748513
miPS-T47Dcm 16.38 μM 48 hours Inhibited proliferation, self-renewal, migration, and invasion of miPS-T47Dcm cells and induced apoptosis PMC8748513
human PBMCs 1 µM 6 hours To investigate the effect of Eganelisib on T cell activation, results showed that Eganelisib reduced the frequency of CD69+ cells. PMC9949793
CT26 cells 0.8 μM 6 hours To evaluate the cytotoxicity of LIC on CT26 cells, results showed that LIC significantly induced apoptosis under laser irradiation PMC8292876
murine splenocytes 1 µM 72 hours To investigate the effect of Eganelisib on T cell proliferation, results showed that Eganelisib reduced the proliferation rate of T cells. PMC9949793
Adipose-derived stem cells (ADSCs) 100 nM 72 hours To evaluate the effect of IPI-549 on the differentiation of adipose-derived stem cells, results showed that IPI-549 significantly reduced lipid accumulation and normalized it to the control level. PMC9809281
SW620/Ad300 cells 5 μM and 10 μM 72 hours IPI-549 significantly sensitized SW620/Ad300 cells to ABCB1 substrates, increased the intracellular concentration of paclitaxel, and inhibited the efflux of paclitaxel. PMC6348084
LLC-PK-MDR1 cells 2.5 μM and 5 μM 72 hours IPI-549 significantly reduced the resistance of LLC-PK-MDR1 cells to ABCB1 substrate drugs. PMC6348084
Bone marrow-derived macrophages (BMDMs) 5 μM Enhanced M2 to M1 macrophage polarization, shown by increased M1 markers (TNF-α and IL-12) and decreased M2 markers (IL-10 and TGF-β). PMC9589917

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J and Balb/c mice 4T1 breast cancer model, B16-GMCSF melanoma model Oral gavage 15 mg/kg Once daily for 14 days To evaluate the inhibitory effect of IPI-549 on tumor growth and metastasis, the results showed that IPI-549 significantly inhibited tumor growth and reduced lung metastasis. PMC5634331
BALB/c Nude mice miPS-LLCcm xenograft model Intraperitoneal injection 5 mg/kg Every other day for 12 days Eganelisib significantly inhibited tumor growth, reduced tumor volume and weight, and induced tumor cell apoptosis PMC8748513
C57BL/6 mice Pancreatic cancer and melanoma models Intravenous injection 15 mg/kg Every three days, continuous treatment IPI-549 NP significantly decreased tumor growth and prolonged host survival in both models, reshaping the suppressive tumor microenvironment by decreasing both suppressive myeloid and plasma cells in the tumor. PMC6815713
BALB/c mice CT26 tumor model Tail vein injection 3.0 mg/kg Once every other day for 15 days To evaluate the antitumor effect of LIC in vivo, results showed that LIC significantly inhibited tumor growth and enhanced immune response PMC8292876
C57BL/6J mice MC38 tumor model Oral 225 µg Daily for 2 weeks To evaluate the tumor suppression effect of IPI-549 combined with PMA-NeoV on MC38 tumors PMC8883272
Mice MMTV-PyMT transgenic mice and 4T1 orthotopic breast cancer model Intravenous injection (IV) PTX (10 mg/kg) and IPI-549 (5 mg/kg) Once every 3 days for 5 doses The combination of Nano-PI with α-PD1 achieved long-term tumor remission, eliminated lung metastasis, and significantly improved mouse survival in MMTV-PyMT transgenic mice. PMC9589917
Athymic mice SW620/Ad300 xenograft tumor model Intraperitoneal injection 3 mg/kg IPI-549 and 15 mg/kg paclitaxel Every 3 days for a total of 4 doses IPI-549 enhanced the anti-tumor effects of paclitaxel on ABCB1-overexpressing MDR SW620/Ad300 tumors. PMC6348084

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03795610 Head and Neck Squamous Cell Ca... More >>rcinoma|Head and Neck Cancer|Head and Neck Carcinoma|Head and Neck Cancer Stage IV|Head and Neck Cancer Stage III|HPV-Related Carcinoma|HPV-Related Malignancy|HPV-Related Squamous Cell Carcinoma Less << PHASE2 RECRUITING 2025-06-23 UC San Diego Moores Cancer Cen... More >>ter, La Jolla, California, 92093, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.89mL

0.38mL

0.19mL

9.46mL

1.89mL

0.95mL

18.92mL

3.78mL

1.89mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories